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A B S T R A C T
Purpose: To present the 13.5-year-survival of an autologous retinal pigment epithelium (RPE) and choroid graft
transplantation with good visual acuity results.
Observations: A 72-year old patient presented with a 5-weeks-old visual acuity deterioration to excentric ﬁnger
counting at half a meter. Fundoscopy showed a ﬁbrotic macular scar, a large subretinal hemorrhage, partly
recent, combined with intraretinal ﬂuid, blood, and hard exudates. RPE-choroid graft surgery was performed,
and visual acuity improved to 20/32, and maintained up until 13.5 years postoperative. Microperimetry per-
formed at the same time revealed a 3.4 dB sensitivity, with ﬁxation on the graft. During the postoperative years
glaucoma developed, an uveitis anterior was treated, and to treat a small Coats' like lesion; one bevacizumab
injection was administered.
Conclusions and importance: A best corrected visual acuity of 20/32 could be achieved and maintained up to 13.5
years after an RPE-choroid graft transplantation, despite an unfavorable preoperative presentation and some
early and late complications. This case is a proof of principle that an RPE-choroid graft harvested from the
midperiphery can support the macular metabolism up to 13.5 after surgery in a patient with severe exudative
AMD. It also represents a rationale for pursuing stem cell derived RPE replacement. Anti-vascular endothelial
growth factor injections are nowadays the mainstay of therapy for choroidal neovascularization and/or small
hemorrhages and oﬀer good results. Nevertheless, selected patients that cannot beneﬁt from this therapy may
proﬁt from an autologous RPE-choroid graft transplantation.
1. Introduction
In an era in which age-related macular degeneration (AMD) can be
detected early with the help of optical coherence tomography (OCT),
and can be treated eﬀectively with several diﬀerent types of anti-VEGF's
(and in selected cases combined with photodynamic therapy (PDT)),1
there are only a few indications for surgical treatment of AMD.2 At the
moment, surgery may be considered in 3 groups of patients. The ﬁrst
group are patients who have a submacular hemorrhage which exists for
more than 14 days, i.e.; which are too late for recombinant tissue
plasminogen activator (rtPA) and gas displacement,3,4 The second
group could be patients which developed during anti-VEGF treatment a
retinal pigment epithelium (RPE) tear involving the fovea,5 or a rela-
tively fresh ﬁbrotic scar. The third group are patients who did not re-
spond to anti-VEGF injections.6 i.e.; All three categories of patients
where the outer retina may not yet be irreversibly damaged. We de-
scribe a patient treated with an autologous full thickness graft of RPE
and choroid, harvested from the periphery and translocated to the
macular area.7
2. Case report
2.1. Pre and postoperative ﬁndings
The 72-year-old patient presented in 2003, with a visual acuity (VA)
drop of her left eye since 5 weeks to excentric ﬁnger counting at half a
meter. With funduscopy a large subretinal hemorrhage was visible with
a ﬁbrotic macular scar, combined with intraretinal ﬂuid, blood and
hard exudates. Retinal pigment epithelium (RPE)-choroid graft surgery
was performed in her left eye, with a silicone oil tamponade.2,7
Shortly after surgery the intraocular pressure increased to 33mmHg
and topical glaucoma treatment (timolol drops) was started. The oil was
removed after 6 months, with again a short intraocular pressure rise to
38mmHg, which was treated with a topical treatment change to Cosopt
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drops (timolol and dorzolamide). Her intra ocular pressure was well
managed by a combination of Cosopt and Monoprost (latanoprost)
drops over the last years, but her optic disc shows glaucomatous da-
mage.
Visual acuity improved to 20/80 at 4 months, 20/50 at 9 months
and 20/40 at 18 months. After three years 20/32 was reached. She
maintained this VA with minor changes over the years up until 9.5
years postoperative, when she presented with a visual acuity drop to
20/200 and an uveitis anterior in her left eye, which responded to to-
pical treatment. Thereafter VA improved again to 20/63. A small Coats'
like lesion8 was then visible on ﬂuorescein angiography nasally of the
optic nerve. The lesion stabilized after one bevacizumab injection. She
had a visual acuity of 20/32 at 13.5 years after surgery. Reading acuity
at that time was 0.42 logRAD and Sine Amsler score was 1 (almost no
distortion).9 On microperimetry a 3.4 dB sensitivity was documented
with ﬁxation on the graft (Fig. 1).
2.2. Materials and methods
The study and data accumulation were conducted with approval of
the Institutional Review Board, and patients' Informed Consent was
obtained.
At the Rotterdam Eye Hospital, The Netherlands, the submacular
ﬁbrovascular scar and hemorrhage was removed through a small
paramacular temporal retinotomy, with a full-thickness graft of RPE
and choroid taken from the midperiphery.2,7
Microperimetry was performed on a Nidek - MP1 microperimeter
with software version 1.7.3. The Goldman III stimulus size was used
with a 200ms projection time. A Cartesian pattern was tested auto-
matically, centered on the graft, with a staircase 4-2-1 treshold strategy.
The brightness of the test stimuli ranged from 0 to 20 dB (400–4
apostilb).10
Fig. 1. Retinal pigment epithelium and choroid graft 13.5 years
after surgery.
Legends: After a temporal retinotomy, the preexistent submacular
hemorrhage and ﬁbrosis were removed and an RPE-choroid graft
was translocated under the macular area of the retina. (A) Fundus
image, (B) Autoﬂuorescence image, (C) Infrared image, (D) Spectral
domain optical coherence tomography: vertical scan. The retinal
layers, including the fovea, above the graft appear to be intact. The
graft itself shows open lumina with some grayshading: depicting the
speciﬁcs of a well vascularized graft.11 (E) Microperimetry. A ma-
cular, 12°, 10-dB pattern, with 45 test loci and a 2° circle as a
ﬁxation target, centered on the macula, was tested. The brightness
of the stimuli ranged from 0 to 20 dB. Mean sensitivity was 3.4 dB,
with a minimum of 0 dB and a maximum of 16 dB.
In the top middle of the graft the autoﬂuorescence shows the
brightest reﬂection, suggesting the presence of lipofuscin in retinal
pigment epithelium. This area on autoﬂuorescence corresponds
with the area on microperimetry with the highest tested sensitivity,
and on OCT the same localization shows good vascularization and
good retinal layer conﬁguration.
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3. Discussion
Fortunately, anti-VEGF therapy is the ﬁrst choice in most patients
and surgery may be an option for some patients where anti-VEGF is not
eﬀective or no longer eﬀective.
This case report documents that visual acuity after a successful
autologous RPE-choroid graft transplantation can be maintained at a
level of 20/32 after 13.5 years, despite several complications in this
patient which were: a small Coats' like lesion, glaucomatous damage,
and uveitis anterior.
This surgery is limited to patients with advanced exudative AMD
which still have a (partly) viable outer retina in the macular area.
Current techniques as spectral domain OCT are therefore almost man-
datory for surgical decision making.11
Even though at the time of presentation anti-VEGF's were not rou-
tinely available, today our patient would neither have been eligible for
anti-VEGF's or rtPA with gas, which underscores the potential long-term
eﬀectiveness of this surgery.
Patient consent
The patient orally consented to publication of the report. This report
does not contain any personal information that could lead to the
identiﬁcation of the patient.
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